Welcome to our dedicated page for TNL Mediagene Warrant SEC filings (Ticker: TNMWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TNL Mediagene WTS (TNMWF) SEC filings page on Stock Titan provides access to regulatory documents filed by TNL Mediagene, the foreign private issuer underlying this warrant. TNL Mediagene reports under the Securities Exchange Act of 1934 and indicates that it files annual reports on Form 20-F, while using Form 6-K for current reports.
In the available Form 6-K filings, TNL Mediagene furnishes corporate information and key exhibits. One filing lists press releases and a shareholder letter as exhibits, while another describes a third amendment to an ordinary share purchase agreement with Tumim Stone Capital LLC, an equity line of credit for its ordinary shares. The amendment changes the valuation method for Tumim’s purchases, allowing a one- or three-trading-day pricing valuation period based on market price and/or volume, with related adjustments to maximum purchase amounts and purchase prices.
On this page, users can review such Form 6-K filings and their exhibits to understand how TNL Mediagene structures its capital-raising activities and communicates with shareholders. The filings also confirm its status as a foreign private issuer and its use of Form 20-F for annual reporting. For holders of TNMWF warrants, these disclosures are important because they describe agreements and corporate actions that may affect the underlying ordinary shares.
Stock Titan enhances this experience by organizing filings by type and date and highlighting key elements of documents such as Form 6-K and, when available, Form 20-F annual reports, so that investors can more easily interpret how TNL Mediagene’s regulatory disclosures relate to the TNMWF warrants.
TNL Mediagene has regained compliance with Nasdaq’s minimum bid price requirement, allowing its shares to remain listed on the Nasdaq Capital Market. Nasdaq confirmed that the company met Listing Rule 5550(a)(2) after the closing bid price of its ordinary shares stayed at $1.00 per share or higher for fifteen consecutive trading days from December 23, 2025 to January 14, 2026.
At the same time, Nasdaq’s Hearings Panel imposed a one-year Discretionary Panel Monitor starting January 20, 2026. During this period, if the company fails any continued listing standard, it will not receive extra time or a cure period; instead, Nasdaq staff will issue a delisting determination, though the company may request a new hearing.
TNL Mediagene filed an amended Form 6-K to update a previously furnished report. The amendment applies only to Exhibit 99.1, which is an amended press release dated September 17, 2025. The company states this change is solely to remove references to certain company names and that no other changes have been made to the original report.
TNL Mediagene filed a Form 6-K describing a third amendment to its equity line of credit ordinary share purchase agreement with Tumim Stone Capital LLC, originally dated November 25, 2024. The amendment, signed on September 14, 2025, changes how Tumim’s purchases of TNL Mediagene ordinary shares are valued.
The company can now choose to have its ordinary shares priced over either a one-trading-day or a three-trading-day valuation period, based on the market price and/or trading volume of the shares. The amendment also makes related changes to the maximum purchase amount and purchase price Tumim will use when buying shares under the equity line arrangement.
FAQ
What is the current stock price of TNL Mediagene Warrant (TNMWF)?
